Shots:
- HUTCHMED has reported enrollment completion in P-II trial of fanregratinib to treat intrahepatic cholangiocarcinoma (IHCC) in pts with FGFR2 fusion or rearrangement; favorable trial results will support NMPA’s NDA submission
- The P-II trial of fanregratinib will assess ORR as 1EP whereas PFS, DCR, DoR, & OS as 2EPs in pts (n=87). Topline data is expected by YE’25, following the first pts dosing in March 2023
- Fanregratinib (HMPL-453) inhibits FGFR 1, 2 & 3 to prevent tumor growth, angiogenesis promotion & anti-tumor resistance
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED’ Orpathys (Savolitinib) Receives the NMPA’s Full Approval for Locally Advanced or Metastatic MET Exon 14 NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
